Key result
Definitive downstream bridging after VA-ECMO linked to ~62% lower 365-day mortality.
Why the study?
Acute myocardial infarction complicated by cardiogenic shock remains highly lethal, prompting evaluation of venoarterial extracorporeal membrane oxygenation as a time-limited bridging platform rather than stand-alone rescue support.
What is the distribution of post-support bridging pathways and associated survival outcomes in adults with non-ECPR infarct-related cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation?
Cohort (n=142)
No
What is the distribution of post-support bridging pathways and associated survival outcomes in adults with non-ECPR infarct-related cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation?
In non-ECPR infarct-related cardiogenic shock supported with VA-ECMO, nearly half of patients achieved 90-day native heart recovery and 14.8% transitioned to definitive surgical, transplant, or LVAD bridging, highlighting that a pathway-based framework captures the clinical utility of VA-ECMO beyond binary mortality.
Answers are grounded in this paper and cite their sources.
Definitive downstream bridging after VA-ECMO was associated with lower 365-day mortality in infarct shock; leaves open optimal selection for prospective trials.
Objective Acute myocardial infarction complicated by cardiogenic shock remains highly lethal. We evaluated venoarterial extracorporeal membrane oxygenation as a time-limited bridging platform rather than as stand-alone rescue support. Methods In this single center retrospective observational cohort study, we retrospectively screened adults who received venoarterial extracorporeal membrane oxygenation for infarct-related cardiogenic shock at Linyi People's Hospital from January 2021 to December 2025. Among 498 extracorporeal membrane oxygenation procedures, 218 infarct-related cardiogenic shock cases were identified. After excluding 76 extracorporeal cardiopulmonary resuscitation cases, 142 patients were analysed. Post-support pathways were classified as recovery surrogate, cardiac surgery, heart transplantation, durable left ventricular assist device support, or bridge failure. Cardiac surgery, heart transplantation, and durable left ventricular assist device support were combined as definitive downstream bridging. Exploratory multivariable logistic regression examined early characteristics associated with recovery surrogate versus bridge failure. Results Mean age was 57.5 ± 11.5 years, and 112 patients (78.9%) were male. Mortality at 28, 90, and 365 days was 33.8%, 40.8%, and 41.5%, respectively. Recovery surrogate was reached in 68 patients (47.9%), bridge failure occurred in 53 (37.3%), heart transplantation in 14 (9.9%), cardiac surgery in 5 (3.5%), and durable left ventricular assist device support in 2 (1.4%). Overall, 21 patients (14.8%) entered definitive downstream bridging. Older age and out-of-hospital cannulation were associated with lower odds of definitive downstream bridging. Among the 121 patients without definitive downstream bridging, higher left ventricular ejection fraction, younger age and lower creatinine were associated with recovery surrogate in multivariable analysis. In exploratory adjusted survival analysis, definitive downstream bridging was associated with lower 365-day mortality. Conclusions Post-support pathways were heterogeneous. A pathway-based framework may better capture the clinical value of venoarterial extracorporeal membrane oxygenation than mortality alone.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) conducted a cohort in Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) (n=142). Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with definitive downstream bridging (heart transplantation, cardiac surgery, or LVAD) vs. No definitive downstream bridging (recovery surrogate or bridge failure) was evaluated on Distribution of post-VA-ECMO bridging pathways (with exploratory 365-day mortality for definitive downstream bridging vs no bridging) (HR 0.38, 95% CI 0.15-0.98, p=0.045). Venoarterial ECMO resulted in 47.9% recovery surrogate, 37.3% bridge failure, and 14.8% definitive downstream bridging, which lowered 365-day mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: